Jyong Biotech Ltd. (MENS): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$3.04M

Year ended 2025-12-31

2023-12-31 Operating Cash Flow (USD) 2025-12-31

Period ended	Operating Cash Flow	Change YoY	Source filing
2025-12-31	-$3.04M	n/m	2026-05-15, From 2025-01-01
2024-12-31	-$3.62M	n/m	2026-05-15, From 2024-01-01
2023-12-31	-$2.60M	n/a	2026-05-15, From 2023-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Cash Flow	Change YoY
Jyong Biotech Ltd. (MENS)	2025-12-31	-$3.04M	n/m
Abvc Biopharma, Inc. (ABVC)	2025-12-31	-$2.99M	n/m
Annovis Bio, Inc. (ANVS)	2025-12-31	-$25.62M	n/m
Nexentis Technologies Inc. (NXTS)	2025-12-31	-$3.81M	n/m
Quoin Pharmaceuticals Ltd. (QNRX)	2025-12-31	-$13.54M	n/m
Evofem Biosciences, Inc. (EVFM)	2025-12-31	-$1.99M	n/m
Emmaus Life Sciences, Inc. (EMMA)	2025-12-31	-$11.0K	n/m
Phio Pharmaceuticals Corp. (PHIO)	2025-12-31	-$7.98M	n/m
BriaCell Therapeutics Corp. (BCTX)	2025-07-31	-$28.17M	n/m

Compare MENS, ABVC, ANVS, NXTS side by side · Screen every company in Pharmaceutical Preparations ↗